drugset
drugset / Trial / NCT03802916

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

NCT03802916 ↗

Phase 2 Completed 30 enrolled ApoPharma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Safety, tolerability, and acceptability of twice-daily dosing with deferiprone delayed-release (DR) tablets in patients with systemic iron overload.

Timeline

Start
2019-03-06
Primary completion
2019-12-04
Completion
2019-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferiprone Small molecule 1000 mg —

Indications

hemosiderosis